{"id":45598,"date":"2022-06-28T17:01:46","date_gmt":"2022-06-28T15:01:46","guid":{"rendered":"https:\/\/pharma-trend.com\/en\/spinex-announces-first-patient-enrollment-in-scone-clinical-trial\/"},"modified":"2022-06-28T17:01:46","modified_gmt":"2022-06-28T15:01:46","slug":"spinex-announces-first-patient-enrollment-in-scone-clinical-trial","status":"publish","type":"post","link":"https:\/\/pharma-trend.com\/en\/spinex-announces-first-patient-enrollment-in-scone-clinical-trial\/","title":{"rendered":"SpineX Announces First Patient Enrollment in SCONE Clinical Trial"},"content":{"rendered":"
\n

\nSCONE trial is assessing safety and efficacy of the SCONE\u2122 device for Neurogenic Bladder<\/i><\/b>\n<\/p>\n

LOS ANGELES–(BUSINESS WIRE)–SpineX Inc., a clinical stage bioelectric medtech company, today announced that the first patient has been enrolled in a pivotal trial evaluating the SCONE\u2122 Device. The pivotal trial, known as SCONE trial, will evaluate the safety and effectiveness of the SCONE\u2122 device for the treatment of Neurogenic bladder. This is the first large-scale pivotal trial testing a non-invasive spinal neuromodulation technology for the treatment of neurogenic bladder. The first patient was enrolled at Rancho Research Institute, the research arm of the prestigious and historic Rancho Los Amigos National Neurorehabilitation Center, Downey, California (https:\/\/www.ranchoresearch.org\/<\/a>).\n<\/p>\n

<\/a>
<\/a><\/p>\n

\nNeurogenic bladder is the most common comorbidity that people suffer after paralysis, and has the largest impact on their quality of life. Surveys suggest that individuals living with paralysis rate improvement in bladder, bowel and sexual function as a higher priority than restoration of ambulation and even resolution of chronic pain. \u201cFor a person in a wheelchair, the inability to walk is the most obvious functional loss, but the impact on quality of life due to neurogenic bladder is unparalleled,\u201d said Dr. Evgeniy Kreydin, MD, Co-Founder, SpineX Inc., and Assistant Professor at University of Southern California, Los Angeles.\n<\/p>\n

\nImpact of neurogenic bladder extends beyond the inability to void as needed or the necessity for lifelong daily repetitive catherizations to empty their bladder. People living with neurogenic bladder have to deal with lost sensation of bladder fullness, low bladder capacity, frequent urination cycles during the day and night, and live with a constant fear of uncontrolled urine leakage. SCONE\u2122 therapy is designed to treat each of these symptoms, thus having a global impact on quality of life.\n<\/p>\n

\n\u201cThe initiation of the SCONE trial is an important milestone in bringing the world\u2019s first non-invasive treatment modality for neurogenic bladder to market,\u201d said Dr. Parag Gad, PhD, Chief Executive Officer of SpineX Inc. \u201cWe are committed to transforming bladder management into a catheter free and leak free world.\u201d\n<\/p>\n

\nAbout SpineX Inc.<\/b>\n<\/p>\n

\nSpineX Inc., a clinical stage bioelectric medtech company developing Noninvasive Spinal Neuromodulation devices as a platform technology. SCONE\u2122 and SCiP\u2122 are two FDA-designated Breakthrough Devices being developed by SpineX for the treatment of adults with Neurogenic Bladder and Children with Cerebral Palsy respectively. To learn more about SpineX and the ongoing trial, visit www.spinex.co<\/a> or follow @spinex_inc on social media.\n<\/p>\n

Contacts<\/b> <\/p>\n

\nParag Gad, parag@spinex.co<\/a>\n<\/p>\n<\/div>\n","protected":false},"excerpt":{"rendered":"

SCONE trial is assessing safety and efficacy of the SCONE\u2122 device for Neurogenic Bladder LOS ANGELES–(BUSINESS WIRE)–SpineX Inc., a clinical stage bioelectric medtech company, today announced that the first patient has been enrolled in a pivotal trial evaluating the SCONE\u2122 Device. The pivotal trial, known as SCONE trial, will evaluate the safety and effectiveness of … [Read more…]<\/a><\/span><\/p>\n","protected":false},"author":4,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[13],"tags":[],"class_list":{"0":"entry","1":"post","2":"publish","3":"author-business","4":"post-45598","6":"format-standard","7":"category-industry"},"yoast_head":"\nSpineX Announces First Patient Enrollment in SCONE Clinical Trial - Pharma Trend<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/pharma-trend.com\/en\/spinex-announces-first-patient-enrollment-in-scone-clinical-trial\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"SpineX Announces First Patient Enrollment in SCONE Clinical Trial - Pharma Trend\" \/>\n<meta property=\"og:description\" content=\"SCONE trial is assessing safety and efficacy of the SCONE\u2122 device for Neurogenic Bladder LOS ANGELES–(BUSINESS WIRE)–SpineX Inc., a clinical stage bioelectric medtech company, today announced that the first patient has been enrolled in a pivotal trial evaluating the SCONE\u2122 Device. The pivotal trial, known as SCONE trial, will evaluate the safety and effectiveness of ... [Read more...]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/pharma-trend.com\/en\/spinex-announces-first-patient-enrollment-in-scone-clinical-trial\/\" \/>\n<meta property=\"og:site_name\" content=\"Pharma Trend\" \/>\n<meta property=\"article:published_time\" content=\"2022-06-28T15:01:46+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/mms.businesswire.com\/media\/20220628005292\/en\/1498384\/21\/OAB_PR_1.jpg\" \/>\n<meta name=\"author\" content=\"Business Wire\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Business Wire\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/spinex-announces-first-patient-enrollment-in-scone-clinical-trial\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/spinex-announces-first-patient-enrollment-in-scone-clinical-trial\\\/\"},\"author\":{\"name\":\"Business Wire\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\"},\"headline\":\"SpineX Announces First Patient Enrollment in SCONE Clinical Trial\",\"datePublished\":\"2022-06-28T15:01:46+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/spinex-announces-first-patient-enrollment-in-scone-clinical-trial\\\/\"},\"wordCount\":421,\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/spinex-announces-first-patient-enrollment-in-scone-clinical-trial\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20220628005292\\\/en\\\/1498384\\\/21\\\/OAB_PR_1.jpg\",\"articleSection\":[\"Industry\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/spinex-announces-first-patient-enrollment-in-scone-clinical-trial\\\/\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/spinex-announces-first-patient-enrollment-in-scone-clinical-trial\\\/\",\"name\":\"SpineX Announces First Patient Enrollment in SCONE Clinical Trial - Pharma Trend\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/spinex-announces-first-patient-enrollment-in-scone-clinical-trial\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/spinex-announces-first-patient-enrollment-in-scone-clinical-trial\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20220628005292\\\/en\\\/1498384\\\/21\\\/OAB_PR_1.jpg\",\"datePublished\":\"2022-06-28T15:01:46+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/spinex-announces-first-patient-enrollment-in-scone-clinical-trial\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/pharma-trend.com\\\/en\\\/spinex-announces-first-patient-enrollment-in-scone-clinical-trial\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/spinex-announces-first-patient-enrollment-in-scone-clinical-trial\\\/#primaryimage\",\"url\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20220628005292\\\/en\\\/1498384\\\/21\\\/OAB_PR_1.jpg\",\"contentUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20220628005292\\\/en\\\/1498384\\\/21\\\/OAB_PR_1.jpg\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/spinex-announces-first-patient-enrollment-in-scone-clinical-trial\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Startseite\",\"item\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"SpineX Announces First Patient Enrollment in SCONE Clinical Trial\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"name\":\"Pharma Trend\",\"description\":\"\",\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\",\"name\":\"Pharma Trend\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"\",\"contentUrl\":\"\",\"caption\":\"Pharma Trend\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\"}},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\",\"name\":\"Business Wire\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"SpineX Announces First Patient Enrollment in SCONE Clinical Trial - Pharma Trend","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/pharma-trend.com\/en\/spinex-announces-first-patient-enrollment-in-scone-clinical-trial\/","og_locale":"en_US","og_type":"article","og_title":"SpineX Announces First Patient Enrollment in SCONE Clinical Trial - Pharma Trend","og_description":"SCONE trial is assessing safety and efficacy of the SCONE\u2122 device for Neurogenic Bladder LOS ANGELES–(BUSINESS WIRE)–SpineX Inc., a clinical stage bioelectric medtech company, today announced that the first patient has been enrolled in a pivotal trial evaluating the SCONE\u2122 Device. The pivotal trial, known as SCONE trial, will evaluate the safety and effectiveness of ... [Read more...]","og_url":"https:\/\/pharma-trend.com\/en\/spinex-announces-first-patient-enrollment-in-scone-clinical-trial\/","og_site_name":"Pharma Trend","article_published_time":"2022-06-28T15:01:46+00:00","og_image":[{"url":"https:\/\/mms.businesswire.com\/media\/20220628005292\/en\/1498384\/21\/OAB_PR_1.jpg","type":"","width":"","height":""}],"author":"Business Wire","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Business Wire","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/pharma-trend.com\/en\/spinex-announces-first-patient-enrollment-in-scone-clinical-trial\/#article","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/spinex-announces-first-patient-enrollment-in-scone-clinical-trial\/"},"author":{"name":"Business Wire","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24"},"headline":"SpineX Announces First Patient Enrollment in SCONE Clinical Trial","datePublished":"2022-06-28T15:01:46+00:00","mainEntityOfPage":{"@id":"https:\/\/pharma-trend.com\/en\/spinex-announces-first-patient-enrollment-in-scone-clinical-trial\/"},"wordCount":421,"publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/spinex-announces-first-patient-enrollment-in-scone-clinical-trial\/#primaryimage"},"thumbnailUrl":"https:\/\/mms.businesswire.com\/media\/20220628005292\/en\/1498384\/21\/OAB_PR_1.jpg","articleSection":["Industry"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/pharma-trend.com\/en\/spinex-announces-first-patient-enrollment-in-scone-clinical-trial\/","url":"https:\/\/pharma-trend.com\/en\/spinex-announces-first-patient-enrollment-in-scone-clinical-trial\/","name":"SpineX Announces First Patient Enrollment in SCONE Clinical Trial - Pharma Trend","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/#website"},"primaryImageOfPage":{"@id":"https:\/\/pharma-trend.com\/en\/spinex-announces-first-patient-enrollment-in-scone-clinical-trial\/#primaryimage"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/spinex-announces-first-patient-enrollment-in-scone-clinical-trial\/#primaryimage"},"thumbnailUrl":"https:\/\/mms.businesswire.com\/media\/20220628005292\/en\/1498384\/21\/OAB_PR_1.jpg","datePublished":"2022-06-28T15:01:46+00:00","breadcrumb":{"@id":"https:\/\/pharma-trend.com\/en\/spinex-announces-first-patient-enrollment-in-scone-clinical-trial\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/pharma-trend.com\/en\/spinex-announces-first-patient-enrollment-in-scone-clinical-trial\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/pharma-trend.com\/en\/spinex-announces-first-patient-enrollment-in-scone-clinical-trial\/#primaryimage","url":"https:\/\/mms.businesswire.com\/media\/20220628005292\/en\/1498384\/21\/OAB_PR_1.jpg","contentUrl":"https:\/\/mms.businesswire.com\/media\/20220628005292\/en\/1498384\/21\/OAB_PR_1.jpg"},{"@type":"BreadcrumbList","@id":"https:\/\/pharma-trend.com\/en\/spinex-announces-first-patient-enrollment-in-scone-clinical-trial\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Startseite","item":"https:\/\/pharma-trend.com\/en\/"},{"@type":"ListItem","position":2,"name":"SpineX Announces First Patient Enrollment in SCONE Clinical Trial"}]},{"@type":"WebSite","@id":"https:\/\/pharma-trend.com\/en\/#website","url":"https:\/\/pharma-trend.com\/en\/","name":"Pharma Trend","description":"","publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/pharma-trend.com\/en\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/pharma-trend.com\/en\/#organization","name":"Pharma Trend","url":"https:\/\/pharma-trend.com\/en\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/","url":"","contentUrl":"","caption":"Pharma Trend"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24","name":"Business Wire"}]}},"_links":{"self":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/45598","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/users\/4"}],"replies":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/comments?post=45598"}],"version-history":[{"count":0,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/45598\/revisions"}],"wp:attachment":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/media?parent=45598"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/categories?post=45598"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/tags?post=45598"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}